Physician profile
Crystal Fredrickson
NPI 1649329996
$5,028.95
in general payments reported to CMS, 2019-2025
25 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $652 · 2022: $821 · 2023: $1,372 · 2024: $1,148 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,261 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,260.82 |
| Education | $294.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $794.13 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $575.48 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $566.60 | 2021-2025 | Tremfya |
| Pfizer INC. | $526.48 | 2021-2025 | |
| Leo Pharma INC. | $445.44 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $377.51 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $327.08 | 2022-2025 | Winlevi |
| Lilly USA, LLC | $318.22 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $198.89 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $145.06 | 2023-2025 | Sotyktu |
| Amgen INC. | $115.12 | 2021-2024 | Otezla |
| Ucb, INC. | $97.35 | 2021-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $86.30 | 2022 | |
| Mayne Pharma Commercial LLC | $83.75 | 2022-2024 | |
| Galderma Laboratories, L.P. | $77.02 | 2021-2025 | Nemluvio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $64.21 | 2021 | |
| Organogenesis INC. | $54.29 | 2024-2025 | Via Matrix |
| Verrica Pharmaceuticals INC. | $35.76 | 2023-2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.92 | 2024 | Spevigo |
| Blueprint Medicines Corporation | $26.56 | 2025 | Ayvakit |
| Nabriva Therapeutics, Plc | $20.05 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.47 | 2022 | |
| Botanix Sb INC | $18.37 | 2025 | Sofdra |
| Incyte Corporation | $18.30 | 2024 | Opzelura |
| Organon LLC | $11.59 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Fredrickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.